| Name | Title | Contact Details |
|---|
MD Revolution harnesses the power of digital health technology to predict, prevent, and reverse chronic disease – and lower healthcare costs. MD Revolution is a transformational digital health provider that delivers a proven population health management service. Our SaaS solution, RevUp, has revolutionized the approach to behavior change for lifestyle diseases including diabetes, obesity, and heart disease. Participants on RevUp receive actionable feedback based on personal health data gathered from wearables and apps. Predictive analytics drive real-time identification of individuals that will or will not achieve desired health outcomes, thereby allowing clinicians and health coaches to focus on participants who require more intensive coaching. Gamification, social and an incentive points system engages employees in their health and builds camaraderie.
T1D Exchange, a nonprofit organization, is a dynamic, multi-purpose, real-world patient data platform designed to accelerate all aspects of drug and device development. T1D Exchange has established a unique model to speed better treatments, therapies and research for type 1 diabetes (T1D). The Exchange consists of an integrated Clinic Network of 65+ clinics across the U.S., a Clinic Registry of 26,000 well-characterized patients, a Biorepository, and Glu, an online community with mobile capabilities for people touched by type 1 diabetes. The T1D Exchange fosters faster and more fluid information transfer and sharing among diabetes patients, physicians, researchers, and pharma, medical device, education, and outreach organizations.
ACON Laboratories, Inc. develops and manufactures a broad range of lateral flow rapid diagnostic tests that are very high quality and competitively priced.
MMM Healthcare is a San Juan, PR-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.